HealthcareMachine Learning4 min reading time

Brainomix E-Lung Analysis Detects Treatment Effects in Phase 2a IPF Trial

Unite.AI
Read full post
Brainomix and Endeavor BioMedicines reported that Brainomix's AI-powered e-Lung tool detected significant treatment effects of taladegib in a Phase 2a idiopathic pulmonary fibrosis trial by analyzing CT scans. The AI analysis revealed improvements in lung volume, fibrosis extent, and disease burden, supporting its use for sensitive, objective endpoints in clinical trials.

More in Healthcare

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources
Healthcare6 min read

NYU-DRP AI Model Predicts Five-Year Breast Cancer Risk From 3D Mammograms

Unite.AI
Healthcare3 min read

Google’s map of every possible DNA typo could speed up rare disease research

Covered by 3 sources